United Kingdom

Krystal Biotech Inc (KRYS.OQ)

KRYS.OQ on NASDAQ Stock Exchange Capital Market

3:09pm GMT
Change (% chg)

$0.17 (+1.63%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Chart for


Krystal Biotech, Inc. is a gene therapy company. The Company is engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. The Company has developed a Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes... (more)


Beta: --
Market Cap(Mil.): $86.32
Shares Outstanding(Mil.): 8.68
Dividend: --
Yield (%): --


  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-Krystal Biotech reports qtrly loss per share $1.26‍​

* Krystal Biotech reports that KB103 received clearance from RAC review and announces third quarter 2017 financial results

13 Nov 2017

BRIEF-Krystal Biotech says KB103 granted orphan drug designation by FDA

* Krystal Biotech’s KB103 granted orphan drug designation by the FDA to treat patients with dystrophic epidermolysis bullosa

07 Nov 2017

Earnings vs. Estimates